101. Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer.
- Author
-
Jackson RS 2nd, Placzek W, Fernandez A, Ziaee S, Chu CY, Wei J, Stebbins J, Kitada S, Fritz G, Reed JC, Chung LW, Pellecchia M, and Bhowmick NA
- Subjects
- Animals, Antineoplastic Agents administration & dosage, Antineoplastic Agents pharmacology, Apoptosis drug effects, Apoptosis genetics, Bone Neoplasms drug therapy, Bone Neoplasms metabolism, Bone Neoplasms secondary, Cell Transformation, Neoplastic metabolism, Disease Progression, Docetaxel, Drug Synergism, Gossypol administration & dosage, Gossypol pharmacology, Gossypol therapeutic use, Humans, Male, Mice, Mice, Transgenic, Myeloid Cell Leukemia Sequence 1 Protein, Orchiectomy, Prostatic Neoplasms metabolism, Prostatic Neoplasms pathology, Proto-Oncogene Proteins c-bcl-2 metabolism, Proto-Oncogene Proteins c-met metabolism, Signal Transduction drug effects, Taxoids administration & dosage, Taxoids pharmacology, Tumor Burden drug effects, Xenograft Model Antitumor Assays, Antineoplastic Agents therapeutic use, Cell Transformation, Neoplastic drug effects, Gossypol analogs & derivatives, Prostatic Neoplasms drug therapy, Proto-Oncogene Proteins c-bcl-2 antagonists & inhibitors
- Abstract
Resistance to available therapeutic agents has been a common problem thwarting progress in treatment of castrate-resistant and metastatic prostate cancer (PCa). Overexpression of the Bcl-2 family members, including Mcl-1, in PCa cells is known to inhibit intracellular mitochondrial-dependent apoptosis. Here we report the development of a novel transgenic mouse model that spontaneously develops prostatic intraepithelial neoplasia and adenocarcinoma by the inducible, conditional knockout of transforming growth factor β receptor type II in stromal fibroblastic cells (Tgfbr2(ColTKO)). The Tgfbr2(ColTKO) prostate epithelia demonstrated down-regulation of luminal and basal differentiation markers, as well as Pten expression and up-regulation of Mcl-1. However, unlike in men, Tgfbr2(ColTKO) prostates exhibited no regression acutely after castration. The administration of Sabutoclax (BI-97C1), a pan-active Bcl-2 protein family antagonist mediated apoptosis in castrate-resistant PCa cells of Tgfbr2(ColTKO) mice and human subcutaneous, orthotopic, and intratibial xenograft PCa models. Interestingly, Sabutoclax had little apoptotic effect on benign prostate tissue in Tgfbr2(ColTKO) and wild-type mice. Sabutoclax was able to block c-Met activation, a critical axis in PCa metastatic progression. Further, Sabutoclax synergistically sensitized PC-3 cells to the cytotoxic effects of docetaxel (Taxotere). Together, these data suggest that Sabutoclax inhibits castrate-resistant PCa alone at the primary and bone metastatic site as well as support sensitivity to docetaxel treatment.
- Published
- 2012
- Full Text
- View/download PDF